



## Supplementary Materials

### Supplementary Figures




**Supplementary Figure S1.** Kaplan- Meier Survival curve for all-cause mortality for patients with LVEF  $\leq$  35% over time by admission Norton scale score. Numbers reflect patients at risk. p value  $<0.0001$ . ANSS= Admission Norton scale score



Patients at risk			
18-20	359	282	187
15-17	51	35	25
≤14	38	23	16


**Supplementary Figure S2.** Kaplan- Meier Survival curve for death without prior defibrillator therapy in patients with LVEF  $\leq 35\%$  over time by admission Norton scale score. Numbers reflect patients at risk. p value  $<0.0001$ . ANSS= Admission Norton scale score

**Supplementary Figure S3.** Kaplan- Meier Survival curve for all-cause mortality over time in high vs. low clinical risk patients with LVEF  $\leq 35\%$ , by admission Norton scale score. Numbers reflect patients at risk. ANSS= Admission Norton scale score. (a) High clinical risk patients:  $\geq 70$  years old and/or baseline serum creatinine values  $\geq 1.5$  mg/dL. p value = 0.00258; (b) Low clinical risk patients:  $<70$  years old and baseline serum creatinine values  $<1.5$  mg/dL. p value =0.163.



Patients at risk			
18-20	183	163	121
15-17	36	27	18
$\leq 14$	29	19	13

(a)



Patients at risk			
18-20	176	165	124
15-17	15	12	11
≤14	9	8	6

(b)

## Supplementary Tables

**Table S1.**The Norton Pressure Sore Risk-Assessment Scale Scoring System

<b>Item</b>	<b>Condition</b>	<b>Value</b>
<b>Physical condition</b>	Good	4
	Fair	3
	Poor	2
	Very bad	1
<b>Mental condition</b>	Alert	4
	Apathetic	3
	Confused	2
	Stuporous	1
<b>Activity</b>	Ambulant	4
	Walks with help	3
	Chair bound	2
	Bedridden	1
<b>Mobility</b>	Full	4
	Slightly impaired	3
	Very limited	2
	Immobile	1
<b>Incontinence</b>	None	4
	Occasional	3
	Usually urinary	2
	Urinary and fecal	1

**Table S2.** Routine programming of implantable defibrillators in the Sheba medical center, Tel-Hashomer

<b>Device</b>	<b>Programming</b>
<b>Biotronik</b>	VT-zone (188 BPM), detection 36 cycled, redetection 30 cycles, Enhancements onset & stability. ATP X2 Bursts (8 x S1, Decrement: 10 ms, R-S1: 85%, Minimum Interval: 200ms) > Shocks: 8 x 40J VF zone (240 bpm), Detection counter: 25 out of 31 cycles, ATP One Shot: Burst, shocks: 8 x 40J Redetection: 10 out of 14 cycles.
<b>Boston scientific</b>	VT zone (170 BPM), Monitor only VF Zone (200 BPM) Duration 2.5 sec, Redetection 1 sec, Shock + Quick convert ATP
<b>SJM-Abbot</b>	VT Zone (185 BPM) No detection Enhancement. Duration – 6 sec Shock if unstable – On. ATP X2 Initial – 8, Coupling Interval – 88% without decrement, Maximum Shock Energy.
<b>Medtronic</b>	VT Zone (167 BPM), monitor only (VTNID 32/40), VF Zone (194 BPM) (VFNID 30/40, VFRNID 9/12) allow discrimination of SVT, Shocks 35J X6 +/- FVT Zone (250 BPM) ATPX8: Burst, R-S1 88%, Shocks 35J X6.

**Table S3.** Baseline characteristics of patients with LVEF ≤ 35% by admission Norton scale score.

<b>Clinical characteristics</b>	<b>overall</b>	<b>ANSS ≤ 14</b>	<b>ANSS 15-17</b>	<b>ANSS 18-20</b>	<b>p value</b>
<b>Study population</b>	n= 448	n= 38	n= 51	n=359	
<b>Age at procedure (years)</b> <b>±SD</b>	67.8 ±11.6	72.6 ±12.9	70±12.4	67 ±11.2	0.005
<b>Female (%)</b>	62 (14)	4 (11)	9 (18)	49 (14)	0.612
<b>Prior myocardial infarction</b> <b>(%)</b>	198 (44)	15 (40)	23 (45)	160 (45)	0.815
<b>Congestive Heart failure</b> <b>(%)</b>	282 (63)	28 (73)	39 (77)	215 (60)	0.030
<b>Atrial fibrillation (%)</b>	136 (31)	12 (32)	16 (31)	108 (30)	0.976
<b>Prior CVA (%)</b>	51 (11)	10 (26)	11 (22)	30 (8)	<0.001
<b>prior TIA (%)</b>	14 (3)	0 (0)	1 (2)	13 (4)	0.415
<b>Dyslipidemia (%)</b>	224 (50)	19 (50)	23 (45)	182 (51)	0.734
<b>Currently on Dialysis (%)</b>	2 (0.4)	1 (3)	1 (2.0)	0 (0)	0.016
<b>Hypertension (%)</b>	246 (55)	22 (58)	28 (55)	196 (55)	0.939

<b>Diabetes mellitus (%)</b>	167 (37)	21 (55)	25 (49)	121 (34)	0.007
<b>Smoker (%)</b>	115 (26)	8 (21)	14 (28)	93 (26)	0.767
<b>BMI (kg/m<sup>2</sup>), ±SD</b>	27 ±5	26 ±4	27 ±5	27 ±5	0.125
<b>GFR MDRD (mL/min/1.73 m<sup>2</sup>), ±SD</b>	62 (31)	63 ±69	56 ±24	62 ±25	0.431
<b>Serum creatinine (mg/dL), ±SD</b>	1.3 ±0.6	1.4 ±0.6	1.4 ±0.7	1.3 ±0.5	0.220
<b>Hemoglobin (g/dL), ±SD</b>	12 (2)	11 ±2	12 ±2	12 ±2	<0.001
<b>Serum albumin (g/dL), ±SD</b>	4 ±0.5	3 ±0.6	4 ±0.5	4 ±0.4	<0.001
<b>LV Ejection fraction (%), ±SD</b>	25 ±7	27± 7	28 ±7	26 ±10	0.783
<b>ACE inhibitors (%)</b>	322 (72)	26 (68)	33 (65)	263 (74)	0.394
<b>Aldosterone antagonists (%)</b>	341 (76)	28 (74)	47 (92)	266 (74)	0.017
<b>Beta blockers (%)</b>	105 (55)	9 (24)	10 (20)	86 (24)	0.790
<b>Antiarrhythmics:</b>					

<b>Class IB (%)</b>	22 (5)	2 (5)	3 (6)	17 (5)	0.934
<b>Class IC (%)</b>	9 (2)	0 (0)	1 (2)	8 (2)	0.648
<b>Class III (%)</b>	232 (52)	22 (58)	24 (47)	186 (52)	0.599
<b>Salicylic acid (%)</b>	10 (2)	0 (0)	1 (2)	9 (3)	0.604

<sup>2</sup> Values are mean  $\pm$  standard deviation, median [IQR] or n (%).

<sup>3</sup> ACE= angiotensin-converting enzyme; ANSS= Admission Norton scale score; BMI= body mass index; CVA= Cerebrovascular accident; GFR= glomerular filtration rate; ICD= implantable cardioverter defibrillator; LVEF= left ventricular ejection fraction; MDRD= Modification of Diet in Renal Disease; TIA= transient ischemic attack.